Migraine Drugs Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The migraine drugs market size has grown strongly in recent years. It will grow from $5.38 billion in 2024 to $5.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to advancements in drug formulations, increased awareness and diagnosis, stress and lifestyle factors, expansion of generic drugs, emergence of cgrp inhibitors.

The migraine drugs market size is expected to see strong growth in the next few years. It will grow to $7.22 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to personalized medicine approaches, telemedicine and remote consultations, healthcare policy and insurance coverage, increasing global migraine burden, combination therapies. Major trends in the forecast period include targeted therapies, telemedicine and remote consultations, patient-centric approaches, digital therapeutics, biosimilars in migraine treatment, clinical research and trials.

The anticipated growth of the migraine drugs market is expected to be propelled by the increasing female population. The female population, encompassing females across all age groups in each country or region during a specific period, plays a crucial role in driving the demand for migraine medications. The prevalence of migraines is notably higher in the female population compared to males, influenced by a combination of genetic, hormonal, and environmental factors. As of 2022, according to the World Population Prospects 2022 released by the United Nations, the global female population is estimated at 4.0 billion, constituting 49.75% of the world population. Projections suggest that females will outnumber males by the year 2049. Consequently, the expanding female population serves as a key driver behind the growth of the migraine drugs market.

The increase in the prevalence of migraines is expected to further contribute to the growth of the migraine drug market in the coming years. Migraine headaches, characterized by recurring episodes of pulsing and pounding pain on one side of the brain, have become more prevalent, leading to a rising demand for effective migraine medications. This surge in prevalence fuels innovation and sales growth as pharmaceutical companies develop and provide therapies to address the needs of an expanding patient population. For instance, as reported in March 2023 by the Migraine Australia 2022-23 Pre-Budget Submissions, a document released by the Australian Treasury, Australia has one of the highest migraine rates globally (28%), affecting one in every four people. This prevalence surpasses that of type 2 diabetes, epilepsy, and asthma combined. Therefore, the increasing prevalence of migraines stands as a significant driver for the growth of the migraine drug market.

Major companies operating in the migraine drugs market are concentrating on the development of innovative products to enhance patient care and gain a competitive advantage. One such example is Zavzpret, a nasal spray medication designed for the acute treatment of migraines with or without aura in adults. For example, in March 2023, Pfizer, a US-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Zavzpret. It is the first and only approved zavegepant (CGRP receptor antagonist) nasal spray for the acute treatment of migraine. Targeting the calcitonin gene-related peptide (CGRP), Zavzpret offers a new treatment option, particularly for individuals experiencing migraines with nausea and vomiting, as well as for those unable to use triptans due to cardiovascular risks.

In May 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired BioHaven Pharmaceutical Holding Company Ltd. for $11.6 billion. Through this acquisition, Pfizer aims to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraines. This strategic move underscores the pharmaceutical industry's commitment to advancing migraine drug development and addressing patient needs.

Major companies operating in the migraine drugs market report are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., AbbVie Inc., AbbVie Inc., Sanofi SA, Novartis AG, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Dr Reddy's Laboratories Ltd., H. Lundbeck A/S, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Neurelis Inc., ALDER BIOPHARMACEUTICALS INC., eNeura Inc., Winston Pharmaceuticals Ltd.

North America was the largest region in the migraine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the migraine drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the migraine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine drugs market consists of sales of analgesics, ergotamines, sumatriptan, and rizatriptan. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Migraine drugs are medications designed to address a neurological condition characterized by intense, throbbing headaches. These drugs operate by targeting various physiological mechanisms responsible for causing migraines.

The primary classes of migraine drugs include triptans, beta-blockers, angiotensin blockers, tricyclics, and anticonvulsants. Triptans, for example, work by altering blood circulation in the brain and modulating how the brain processes pain signals. These drugs can be administered through various routes, such as oral or injectable, and are utilized by diverse end-users, including hospitals and clinics, retail pharmacies, online pharmacies, and others.

The migraine drugs market research report is one of a series of new reports that provides migraine drugs market statistics, including migraine drugs industry global market size, regional shares, competitors with a migraine drugs market share, detailed migraine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the migraine drugs industry. This migraine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.